Surface Topographies of Glaucoma Drainage Devices and Their Influence on Human Tenon Fibroblast Adhesion

Choritz, Lars; Koynov, Kaloian; Renieri, Giulia; Barton, Keith; Pfeiffer, Norbert; Thieme, Hagen

doi:10.1167/iovs.09-4759

Cited by 47 publications

(32 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The different designs of the implants could also play a role. The Ahmed tube is valved and might induce more fibrosis compared to the non-valved BV glaucoma implant (Choritz et al 2010). Another possible explanation for the difference in EC loss might be the different material of the glaucoma drainage devices.…”

Section: Discussionmentioning

confidence: 99%

Corneal endothelial cell loss after Baerveldt glaucoma drainage device implantation in the anterior chamber

Tan

Webers

Berendschot

et al. 2016

Acta Ophthalmologica

View full text Add to dashboard Cite

PurposeTo investigate central and peripheral corneal endothelial cell density (ECD) in relation to Baerveldt (BV) glaucoma drainage device (GDD) tube corneal (TC) distance.MethodsProspective study of all patients scheduled for glaucoma tube surgery with 36 months follow‐up. A BV GDD was inserted into the anterior chamber (AC). Anterior segment optical coherence tomography (AS‐OCT) scans were made to determine the TC distance. Central and peripheral ECD was measured, preoperatively and at 3, 6, 12, 24 and 36 months postoperatively.ResultsFifty‐three eyes were included [primary open‐angle glaucoma, (n = 13); secondary glaucoma, (n = 30); and primary angle‐closure glaucoma, (n = 10)]. Central ECD significantly decreased during follow‐up, with a mean decrease of 4.54% per year (p < 0.001), and 6.57% in the peripheral quadrant closest to the BV GDD tube (PQC, p < 0.001). In the PQC, a yearly decrease of 1.57% was shown after transiridial tube placement versus 7.43% after placement ‘free’ into the AC (p = 0.006). Endothelial cell (EC) loss was related to TC distance (mean 1.69 mm), with a central loss of 6.20% and 7.25% in the PQC per year with shorter TC distances, versus a central loss of 4.11% and 5.77% in the PQC per year with longer TC distances (outside mean ± 2SD, p < 0.001). A difference in EC loss by glaucoma subtype was not identified.ConclusionThe TC distance is of significant influence on corneal ECD, a shorter TC distance causing more severe EC loss, especially in the PQC. Transiridial placement of the BV GDD tube seems safer than placement ‘free’ into the AC.

show abstract

Section: Discussionmentioning

confidence: 99%

Corneal endothelial cell loss after Baerveldt glaucoma drainage device implantation in the anterior chamber

Tan

Webers

Berendschot

et al. 2016

Acta Ophthalmologica

View full text Add to dashboard Cite

show abstract

“…32,33 Furthermore, electron microscopy comparing the Ahmed-FP7 end plate with the Baerveldt-350 implant found that it had a root-mean-square roughness 10-fold greater, resulting in increased in vitro tenon fibroblast adhesion. 34 Antimetabolites have been trialed in aqueous drainage device implantation to prevent encapsulation but failed to show improved IOP and had a higher incidence of hypotony and graft melt. 5,8,32 Bleb histology has been cited as an important factor in the long-term success of aqueous drainage devices, with encapsulation reducing filtration and increasing the need for medications.…”

Section: Discussionmentioning

confidence: 99%

The Ahmed Versus Baerveldt Study

Christakis

Tsai

Kalenak³

et al. 2013

Ophthalmology

176

View full text Add to dashboard Cite

show abstract

“…These include its large surface area, low, curved profile, and polished surface. 9,10 In addition, it has been postulated that complete occlusion of non-valved implants such as the BGI for the first four to six weeks postoperatively limits inflammatory mediators from entering the bleb with the consequent reduction in the likelihood of bleb encapsulation. 11 Success rates reported for the AGV range from 68 to 100% and for the BGI from 43 – 100% with such rates being highly dependent upon the length of follow-up, type of glaucoma, and success criteria.…”

mentioning

confidence: 99%

Three-year Treatment Outcomes in the Ahmed Baerveldt Comparison Study

et al. 2014

Self Cite

View full text Add to dashboard Cite

Purpose To compare three year outcomes and complications of the Ahmed FP7 Glaucoma Valve (AGV) and Baerveldt 101–350 Glaucoma Implant (BGI) for the treatment of refractory glaucoma. Design Multicenter randomized controlled clinical trial. Participants 276 patients; 143 in the AGV group and 133 in the BGI group. Methods Patients aged 18–85 years with refractory glaucoma and intraocular pressures (IOPs) ≥18 mmHg in whom an aqueous shunt was planned were randomized to either an AGV or a BGI. Main Outcome Measures IOP, visual acuity, supplemental medical therapy, complications, and failure (IOP > 21 mmHg or not reduced by 20% from baseline, IOP ≤ 5 mmHg, reoperation for glaucoma or removal of implant, or loss of light perception vision). Results At 3 years, IOP (mean ± standard deviation) (SD) was 14.3 ± 4.7 mmHg (AGV group) and 13.1 ± 4.5 mmHg (BGI group) (p = 0.086) on 2.0 ± 1.4 and 1.5 ± 1.4 glaucoma medications respectively (p = 0.020). The cumulative probabilities of failure were 31.3% (standard error = 4.0%) (SE) (AGV) and 32.3% (4.2%) (BGI) (p = 0.99). Postoperative complications associated with reoperation or vision loss of ≥ 2 Snellen lines occurred in 24 patients (22%) (AGV) and 38 patients (36%) (BGI) (p = 0.035). The mean change in the Logarithm of the Minimum Angle of Resolution visual acuity (logMAR VA) at 3 years was similar (AGV: 0.21 ± 0.88, BGI: 0.26 ± 0.74) in the two treatment groups at 3 years (p=0.66). The cumulative proportion of patients (SE) undergoing reoperation for glaucoma prior to the three year postoperative time point was 14.5% (3.0%) in the AGV group compared to 7.6% (2.4%) in the BGI group (p=0.053, log-rank). The relative risk of reoperation for glaucoma in the AGV group was 2.1 times that of the BGI group (95% Confidence Interval:1.0–4.8, p=0.045; Cox proportional hazards regression). Conclusions AGV implantation was associated with the need for significantly greater adjunctive medication to achieve equal success relative to BGI implantation and resulted in a greater relative risk of reoperation for glaucoma. More subjects experienced serious postoperative complications in the BGI group than in the AGV group.

show abstract

Surface Topographies of Glaucoma Drainage Devices and Their Influence on Human Tenon Fibroblast Adhesion

Cited by 47 publications

References 42 publications

Corneal endothelial cell loss after Baerveldt glaucoma drainage device implantation in the anterior chamber

Corneal endothelial cell loss after Baerveldt glaucoma drainage device implantation in the anterior chamber

The Ahmed Versus Baerveldt Study

Three-year Treatment Outcomes in the Ahmed Baerveldt Comparison Study

Contact Info

Product

Resources

About